<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515292</url>
  </required_header>
  <id_info>
    <org_study_id>142 /181/ 20.05.2014</org_study_id>
    <nct_id>NCT02515292</nct_id>
  </id_info>
  <brief_title>Evaluation of Infants With Intrauterine Growth Restriction</brief_title>
  <acronym>ModeInfIUGR</acronym>
  <official_title>Multidimensional Modeling in Evaluation of Infants With Intrauterine Growth Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iuliu Hatieganu University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iuliu Hatieganu University of Medicine and Pharmacy</source>
  <brief_summary>
    <textblock>
      Purpose: Clinical assessment (anthropometric) and paraclinical (biochemical and immunological
      by dosing serum insuline growth factors IGF1 and IGF2 and their receptors) of neonates with
      intrauterine growth restriction (IUGR) and the integration in a multidimensional statistical
      model .

      Objectives:

        1. IGF1 and IGF2 evaluation of serum and IGF1 receptor, IGF2 receptor and IGF2 receptor
           gene expression in cord blood from newborns with intrauterine growth restriction (IUGR).
           (Prospective)

        2. Evaluation and monitoring of anthropometric, clinical (non-cardiac morbidity) and
           paraclinical. (Retrospective &amp; prospective)

        3. Evaluation and monitoring of morphological and functional by echocardiography.
           (Prospective)

        4. Integrating multidimensional clinical and paraclinical parameters in a statistical model
           for evaluating newborn with intrauterine growth restriction.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of serum IGF2</measure>
    <time_frame>baseline</time_frame>
    <description>serum IGF2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of IGF2 receptors</measure>
    <time_frame>baseline</time_frame>
    <description>serum IGF2 receptors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetic evaluation</measure>
    <time_frame>baseline</time_frame>
    <description>Number of subjects homozygous (A or G) and heterozygous (A/G) using forward primer: 5'- CTTGGACTTTGAGTCAAATTGG-3' and reverse primer: 5'-GGTCGTGCCAATTACATTTCA-3' genetic expression of IGF2 receptors. The groups will be evaluated in regards of polymorphism and allele frequencies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessment</measure>
    <time_frame>baseline</time_frame>
    <description>Number of cases with respiratory distress, hyperbilirubinemia, early and late sepsis, hypoglicemia, necrozant enterocolitis or other co-morbidities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac morphological and functional evaluation</measure>
    <time_frame>baseline and follow-up (1 month and/or 6 months)</time_frame>
    <description>Eco cardiac measurements will be performed to all participants and the morphological and functional data will be recorded baseline for all participant (IUGR and controls). As results number of subjects with cardiac morphological and functional evaluation will be according with subjects included in the study and those subjects with cardiac modification or those from case group will be evaluated dynamically.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intrauterine Growth Restriction</condition>
  <arm_group>
    <arm_group_label>IUGR: newborn with intrauterine growth restriction</arm_group_label>
    <description>Inclusion criteria:
newborn infants with symmetrical (both weight and height lower than 10th percentile) or asymmetrical (birth weight is lower than 10th percentile but height and age-appropriated height) intrauterine growth restriction
agreement of the parents that their child to be included in the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control: newborn without intrauterine growth restriction</arm_group_label>
    <description>Inclusion criteria:
- matches newborn without intrauterine growth restriction in terms of gender and gestational age as IUGR group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Population with IUGR from a 3rd level maternity from Nord-West of Romania
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newborns with intrauterine growth restriction (IUGR): weight below the 10th percentile
             for gestational age

          -  parental consent for enrollment

        Exclusion Criteria:

          -  IUGR neonates in the context chromosomopathies: trisomy 21, trisomy 18.

          -  neonates with congenital heart disease

          -  twins

          -  refusal of parents for participation to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriela Zaharie, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Iuliu Hațieganu Medicine and pharmacy University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica Gabriela Hășmășanu, MD</last_name>
    <phone>+40741985974</phone>
    <email>popa.monica@umfcluj.ro</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sorana D. Bolboacă, PhD Habil</last_name>
    <phone>+40750774506</phone>
    <email>sbolboaca@umfcluj.ro</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neonatal-Ward, 1st Gynecology Clinic</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Hăşmăşanu, MD</last_name>
      <phone>+40741985974</phone>
      <email>popa.monica@umfcluj.ro</email>
    </contact>
    <contact_backup>
      <last_name>Sorana D. Bolboacă, PhD Habil, MD</last_name>
      <phone>+40750774506</phone>
      <email>sbolboaca@umfcluj.ro</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>August 4, 2015</last_update_submitted>
  <last_update_submitted_qc>August 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iuliu Hatieganu University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Hășmășanu Monica Gabriela</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>IUGR (intrauterine growth restriction)</keyword>
  <keyword>IGF2 (insulin-like growth factor 2)</keyword>
  <keyword>morbidity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

